Nexalin Technology (NASDAQ:NXL) Earns Hold Rating from Maxim Group

Nexalin Technology (NASDAQ:NXL)‘s stock had its “hold” rating reiterated by stock analysts at Maxim Group in a report issued on Thursday,Benzinga reports.

Nexalin Technology Stock Performance

Shares of NASDAQ NXL traded up $0.05 during trading hours on Thursday, hitting $4.20. The stock had a trading volume of 614,726 shares, compared to its average volume of 1,421,484. The company has a market capitalization of $54.01 million, a P/E ratio of -6.56 and a beta of 3.78. The firm’s 50-day moving average price is $2.45 and its two-hundred day moving average price is $1.56. Nexalin Technology has a 52 week low of $0.25 and a 52 week high of $4.49.

Nexalin Technology (NASDAQ:NXL) last announced its quarterly earnings results on Friday, November 8th. The company reported ($0.23) EPS for the quarter. Nexalin Technology had a negative return on equity of 187.59% and a negative net margin of 3,407.98%. The business had revenue of $0.04 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Nexalin Technology stock. CVI Holdings LLC acquired a new stake in shares of Nexalin Technology, Inc. (NASDAQ:NXL) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 55,462 shares of the company’s stock, valued at approximately $94,000. CVI Holdings LLC owned approximately 0.52% of Nexalin Technology at the end of the most recent quarter. Hedge funds and other institutional investors own 0.65% of the company’s stock.

About Nexalin Technology

Nexalin Technology, Inc, a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia.